

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

NCT05430035

Status	RECRUITING
Phase	Early Phase 1
Sponsor	West Virginia University
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (14)

- Subjects must have histologically or cytologically confirmed gallbladder adenocarcinoma AND inadvertent spillage of bile or intentional decompression during cholecystectomy OR tumors extending through the serosa of the gallbladder (T3/T4) OR poorly differentiated gallbladder adenocarcinoma.
- ECOG Performance status d 2
- Subjects must have normal organ and marrow function as defined below:
 - Hemoglobin e 10.0 g/dl
 - Leukocytes e 3,000/mcL
- ... and 9 more (see full listing online)

Exclusion (8)

- Prior systemic therapy for gallbladder adenocarcinoma
- Subjects receiving any other investigational agents.
- Subjects with known or suspected metastatic disease
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to MMC or other agents used in this study.
- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- ... and 3 more (see full listing online)

Locations (1 total)

West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States